• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Aurora Cannabis to Host Fourth Quarter and Fiscal Year 2025 Investor Conference Call and File Related Year End Information

    6/3/25 4:15:00 PM ET
    $ACB
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $ACB alert in real time by email

    NASDAQ | TSX: ACB

    EDMONTON, AB, June 3, 2025 /PRNewswire/ - Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ:ACB) (TSX:ACB), the Canadian based leading global medical cannabis company, announced today that it has scheduled a conference call to discuss the results for its fourth quarter and fiscal year 2025 on Wednesday, June 18, 2025 at 8:00 a.m. Eastern Time | 6:00 a.m. Mountain Time. The Company will report its financial results for the fourth quarter fiscal year 2025 before the opening of markets that same day.

    Aurora logo (CNW Group/Aurora Cannabis Inc.)

    Conference Call Details

    DATE:

    Wednesday, June 18, 2025

    TIME:

    8:00 a.m. Eastern Time | 6:00 a.m. Mountain Time

    WEBCAST:

    Click Here

    Miguel Martin, Executive Chairman and Chief Executive Officer, and Simona King, Chief Financial Officer, will host the conference call and question and answer period. This weblink has also been posted to the Company's "Investor Info" link at https://www.auroramj.com/investors/ under "Events".

    About Aurora Cannabis

    Aurora is opening the world to cannabis, serving both the medical and consumer markets across Canada, Europe, Australia and New Zealand. Headquartered in Edmonton, Alberta, Aurora is a pioneer in global cannabis, dedicated to helping people improve their lives. The Company's adult- use brand portfolio includes Drift, San Rafael '71, Daily Special, Tasty's, Being and Greybeard. Medical cannabis brands include MedReleaf, CanniMed, Aurora and Whistler Medical Marijuana Co, as well as international brands, Pedanios, IndiMed and CraftPlant. Aurora also has a controlling interest in Bevo Farms Ltd., North America's leading supplier of propagated agricultural plants. Driven by science and innovation, and with a focus on high-quality cannabis products, Aurora's brands continue to break through as industry leaders in the medical, wellness and adult recreational markets wherever they are launched. Learn more at www.auroramj.com and follow us on X and LinkedIn.

    Aurora's common shares trade on the NASDAQ and TSX under the symbol "ACB".

    Forward Looking Statements

    This news release includes statements containing certain "forward-looking information" within the meaning of applicable securities law ("forward-looking statements"). Forward-looking statements are frequently characterized by words such as "plan", "continue", "expect", "project", "intend", "believe", "anticipate", "estimate", "may", "will", "potential", "proposed" and other similar words, or statements that certain events or conditions "may" or "will" occur. Forward-looking statements made in this news release include, but are not limited to, statements regarding the timing of the release of the Company's financial statements for fourth quarter and fiscal year ended March 31, 2025 and scheduling of the conference call to discuss results.

    These forward-looking statements are only predictions. Forward looking information or statements contained in this news release have been developed based on assumptions management considers to be reasonable. Material factors or assumptions involved in developing forward-looking statements include, without limitation, publicly available information from governmental sources as well as from market research and industry analysis and on assumptions based on data and knowledge of this industry which the Company believes to be reasonable. Forward-looking statements are subject to a variety of risks, uncertainties and other factors that management believes to be relevant and reasonable in the circumstances could cause actual events, results, level of activity, performance, prospects, opportunities or achievements to differ materially from those projected in the forward-looking statements. These risks include, but are not limited to, the timing, magnitude and duration of potential new or increased tariffs imposed on goods imported from Canada into the United States, the ability to retain key personnel, the ability to continue investing in infrastructure to support growth, the ability to obtain financing on acceptable terms, the continued quality of our products, customer experience and retention, the development of third party government and non-government consumer sales channels, management's estimates of consumer demand in Canada and in jurisdictions where the Company exports, expectations of future results and expenses, the risk of successful integration of acquired business and operations (with respect to the Transaction and more generally with respect to future acquisitions), management's estimation that SG&A will grow only in proportion of revenue growth, the ability to expand and maintain distribution capabilities, the impact of competition, the general impact of financial market conditions, the yield from cannabis growing operations, product demand, changes in prices of required commodities, competition, and the possibility for changes in laws, rules, and regulations in the industry, epidemics, pandemics or other public health crises and other risks, uncertainties and factors set out under the heading "Risk Factors" in the Company's annual information from dated June 20, 2024 (the "AIF") and filed with Canadian securities regulators available on the Company's issuer profile on SEDAR+ at www.sedarplus.com and filed with and available on the SEC's website at www.sec.gov. The Company cautions that the list of risks, uncertainties and other factors described in the AIF is not exhaustive and other factors could also adversely affect its results. Readers are urged to consider the risks, uncertainties and assumptions carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on such information. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities law.

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/aurora-cannabis-to-host-fourth-quarter-and-fiscal-year-2025-investor-conference-call-and-file-related-year-end-information-302472440.html

    SOURCE Aurora Cannabis Inc.

    Get the next $ACB alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ACB

    DatePrice TargetRatingAnalyst
    12/11/2024Buy
    TD Cowen
    2/9/2024Hold → Buy
    Canaccord Genuity
    9/21/2022Sell → Hold
    Canaccord Genuity
    6/24/2022Neutral → Overweight
    Cantor Fitzgerald
    6/6/2022Sell → Hold
    Stifel
    11/10/2021$9.60 → $10.75Neutral
    Cantor Fitzgerald
    10/28/2021$9.50 → $9.60Neutral
    Cantor Fitzgerald
    10/5/2021$8.30 → $9.50Neutral
    Cantor Fitzgerald
    More analyst ratings

    $ACB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Aurora Cannabis Inc. (Amendment)

      SC 13G/A - AURORA CANNABIS INC (0001683541) (Subject)

      2/14/23 11:28:04 AM ET
      $ACB
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13G filed by Aurora Cannabis Inc.

      SC 13G - AURORA CANNABIS INC (0001683541) (Subject)

      6/1/22 10:14:29 AM ET
      $ACB
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13G/A filed by Aurora Cannabis Inc. (Amendment)

      SC 13G/A - AURORA CANNABIS INC (0001683541) (Subject)

      2/14/22 3:54:29 PM ET
      $ACB
      Medicinal Chemicals and Botanical Products
      Health Care

    $ACB
    SEC Filings

    See more
    • SEC Form 6-K filed by Aurora Cannabis Inc.

      6-K - AURORA CANNABIS INC (0001683541) (Filer)

      6/4/25 10:31:15 AM ET
      $ACB
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 6-K filed by Aurora Cannabis Inc.

      6-K - AURORA CANNABIS INC (0001683541) (Filer)

      5/27/25 6:49:58 AM ET
      $ACB
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 6-K filed by Aurora Cannabis Inc.

      6-K - AURORA CANNABIS INC (0001683541) (Filer)

      3/20/25 9:27:09 AM ET
      $ACB
      Medicinal Chemicals and Botanical Products
      Health Care

    $ACB
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Aurora Expands Medical Cannabis Offerings in Australia with the Launch of IndiMed TEMPO 22

      NASDAQ | TSX: ACB  Canada's Largest Medical Cannabis Company Adds Two New Cultivars to Popular Brand Portfolio in the Australian Market EDMONTON, AB, June 5, 2025 /PRNewswire/ - Aurora Cannabis Inc. (NASDAQ:ACB) (TSX:ACB), the Canadian-based leading global medical cannabis company, has expanded their popular IndiMed brand with the launch of IndiMed TEMPO 22, available through the company's subsidiary, MedReleaf Australia. With the same consistent quality and reliable supply, this new 22% THC potency creates a greater range of treatment options available to prescribers. "Expanding our portfolio in the value segment in Australia reinforces our commitment to meet increasingly diversified pati

      6/5/25 7:00:00 AM ET
      $ACB
      Medicinal Chemicals and Botanical Products
      Health Care
    • Aurora Cannabis to Host Fourth Quarter and Fiscal Year 2025 Investor Conference Call and File Related Year End Information

      NASDAQ | TSX: ACB EDMONTON, AB, June 3, 2025 /PRNewswire/ - Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ:ACB) (TSX:ACB), the Canadian based leading global medical cannabis company, announced today that it has scheduled a conference call to discuss the results for its fourth quarter and fiscal year 2025 on Wednesday, June 18, 2025 at 8:00 a.m. Eastern Time | 6:00 a.m. Mountain Time. The Company will report its financial results for the fourth quarter fiscal year 2025 before the opening of markets that same day. Conference Call Details DATE: Wednesday, June 18, 2025

      6/3/25 4:15:00 PM ET
      $ACB
      Medicinal Chemicals and Botanical Products
      Health Care
    • Aurora to Participate in TD Cowen's 9th Annual Future of the Consumer Conference

      NASDAQ | TSX: ACB Canada's Largest Medical Cannabis Company to Discuss Key Trends, Market Opportunities and the Future of the Global Cannabis Industry EDMONTON, AB, May 27, 2025 /PRNewswire/ - Aurora Cannabis Inc. (NASDAQ:ACB) (TSX:ACB), the Canadian-based leading global medical cannabis company, will participate in TD Cowen's 9th Annual Future of the Consumer Conference in New York City, NY. Simona King, Chief Financial Officer at Aurora, will take part in a fireside chat and one-on-one meetings with investors on June 3, 2025, at 2:45pm EST. Conference Call Details DATE: Tues

      5/27/25 7:00:00 AM ET
      $ACB
      Medicinal Chemicals and Botanical Products
      Health Care

    $ACB
    Financials

    Live finance-specific insights

    See more
    • Aurora Cannabis to Host Fourth Quarter and Fiscal Year 2025 Investor Conference Call and File Related Year End Information

      NASDAQ | TSX: ACB EDMONTON, AB, June 3, 2025 /PRNewswire/ - Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ:ACB) (TSX:ACB), the Canadian based leading global medical cannabis company, announced today that it has scheduled a conference call to discuss the results for its fourth quarter and fiscal year 2025 on Wednesday, June 18, 2025 at 8:00 a.m. Eastern Time | 6:00 a.m. Mountain Time. The Company will report its financial results for the fourth quarter fiscal year 2025 before the opening of markets that same day. Conference Call Details DATE: Wednesday, June 18, 2025

      6/3/25 4:15:00 PM ET
      $ACB
      Medicinal Chemicals and Botanical Products
      Health Care
    • Aurora to Participate in TD Cowen's 9th Annual Future of the Consumer Conference

      NASDAQ | TSX: ACB Canada's Largest Medical Cannabis Company to Discuss Key Trends, Market Opportunities and the Future of the Global Cannabis Industry EDMONTON, AB, May 27, 2025 /PRNewswire/ - Aurora Cannabis Inc. (NASDAQ:ACB) (TSX:ACB), the Canadian-based leading global medical cannabis company, will participate in TD Cowen's 9th Annual Future of the Consumer Conference in New York City, NY. Simona King, Chief Financial Officer at Aurora, will take part in a fireside chat and one-on-one meetings with investors on June 3, 2025, at 2:45pm EST. Conference Call Details DATE: Tues

      5/27/25 7:00:00 AM ET
      $ACB
      Medicinal Chemicals and Botanical Products
      Health Care
    • Aurora Cannabis Announces Fiscal 2025 Third Quarter Results

      NASDAQ | TSX: ACB Reports Total Net Revenue1 of $88.2 Million, up 37% YoY, Including Record Net Revenue1 of $68.1 Million in Global Medical Cannabis, up 51% YoYGenerates Record Net Income of $31.2 Million, up 282% YoY, and Record Adjusted EBITDA1 of $23.1 Million, up 316% YoYAchieves Target of Positive Free Cash Flow1 in Q3, Generating $27.4 Million of Free Cash Flow1Maintains Strong Balance Sheet with $180 Million of Cash and Debt-Free Cannabis Business2EDMONTON, AB, Feb. 5, 2025 /PRNewswire/ - Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ:ACB) (TSX:ACB), a leading Canada-based global medical cannabis company, today announced its financial and operational results for the third qu

      2/5/25 7:00:00 AM ET
      $ACB
      Medicinal Chemicals and Botanical Products
      Health Care

    $ACB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • TD Cowen initiated coverage on Aurora Cannabis

      TD Cowen initiated coverage of Aurora Cannabis with a rating of Buy

      12/11/24 10:35:16 AM ET
      $ACB
      Medicinal Chemicals and Botanical Products
      Health Care
    • Aurora Cannabis upgraded by Canaccord Genuity

      Canaccord Genuity upgraded Aurora Cannabis from Hold to Buy

      2/9/24 6:09:16 AM ET
      $ACB
      Medicinal Chemicals and Botanical Products
      Health Care
    • Aurora Cannabis upgraded by Canaccord Genuity

      Canaccord Genuity upgraded Aurora Cannabis from Sell to Hold

      9/21/22 9:02:55 AM ET
      $ACB
      Medicinal Chemicals and Botanical Products
      Health Care

    $ACB
    Leadership Updates

    Live Leadership Updates

    See more
    • Rubicon Organics Announces Appointment of Glen Ibbott as Interim CFO

      VANCOUVER, British Columbia, May 15, 2025 (GLOBE NEWSWIRE) -- Rubicon Organics Inc. (TSXV:ROMJ) (OTCQX:ROMJF) ("Rubicon Organics" or the "Company"), a licensed producer focused on cultivating and selling organic certified and premium cannabis products, today announced the appointment of Glen Ibbott, a cannabis industry veteran and former Chief Financial Officer of Aurora Cannabis Inc. (TSX:ACB, NASDAQ:ACB) as its Interim Chief Financial Officer. Janis Risbin, current CFO, will be stepping away from her full-time role effective today. She will remain in an advisory role over the next few months to ensure a smooth transition of responsibilities to Mr. Ibbott. "Glen's leadership at Aurora C

      5/15/25 7:00:00 AM ET
      $ACB
      Medicinal Chemicals and Botanical Products
      Health Care
    • Aurora CEO Miguel Martin takes on additional role as Executive Chairman of Board of Directors

      NASDAQ | TSX: ACB Outgoing Chairman Ron Funk appointed Lead Independent Director, as part of Board leadership transition EDMONTON, AB, Sept. 20, 2024 /PRNewswire/ - Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ:ACB) (TSX:ACB), a leading Canada-based global medical cannabis company, today announced the appointments of CEO Miguel Martin to the additional role of Executive Chairman and outgoing Chairman Ron Funk as Lead Independent Director. Both appointments follow unanimous votes by Aurora's Board and are effective immediately. Mr. Martin has served as Chief Executiv

      9/20/24 7:00:00 AM ET
      $ACB
      Medicinal Chemicals and Botanical Products
      Health Care
    • Aurora Cannabis Announces Results of 2024 Annual General and Special Meeting

      NASDAQ | TSX: ACB EDMONTON, AB, Aug. 12, 2024 /PRNewswire/ -  Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ:ACB) (TSX:ACB), a leading Canada-based global medical cannabis company, is pleased to announce the voting results from its Annual General and Special Meeting of Shareholders (the "Meeting") held Friday August 9, 2024 by virtual webcast. The total number of shares represented by shareholders present in person (virtually) and by proxy at the Meeting was 14,855,306, representing 27.23% of Aurora's issued and outstanding common shares as of the record date. All of

      8/12/24 7:00:00 AM ET
      $ACB
      Medicinal Chemicals and Botanical Products
      Health Care